📋 Tender Overview
Progress New Assets (One Pre-New Molecular Entity And One First-Time-In-Human Start) For Tuberculosis That Act Synergistically With Bedaquiline, Cytochrome Bc Or Cytochrome Bd Inhibitors
Novel Drug Combination Treatment For Tuberculosistuberculosis (Tb) Is Still The World~S Most Deadly Infectious Disease, And Multidrug-Resistant Tb Poses A Serious Threat To Global Health. Treatment Options Are Limited And Often Associated With Many Adverse Effects From The Drugs. The Overall Objective Of The Eu-Funded Respiritb Project Is To Find New Drug Candidates For Efficient Combination Treatment Against Tb And Multidrug-Resistant Tb. The Drug Combination Will Target The Energy Metabolism Of Mycobacterium Tuberculosis (Mtb), Using Recently Discovered Inhibitors Of The Mtb Respiratory Pathway. It Will Also Target Host Factors That Are Essential For The Intracellular Survival Of Mtb. The Project Presents A Comprehensive Plan To Find Novel Strategies To Combat Tb, Shorten Treatment Time And Reduce Incidences Of Drug Resistance.
Funded Under
Societal Challenges - Health, Demographic Change And Well-Being
Total Cost
€ 9 962 900,00
Eu Contribution
€ 6 840 000,00
Coordinated By
Academisch Ziekenhuis Leiden
Netherlands
Start Date
1 May 2019
End Date
30 April 2027
Objective
Despite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the world’s leading infectious disease killer worldwide. In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health. Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs. Moreover, due to the long treatment duration, compliance is low leading to more AMR in TB. Thus, there is an acute need for the development of a novel combination regimen with an indication for effective, shorter, and safer treatment of all forms of TB. The overall objective of RESPIRI-TB is to find new drug candidates as potential components of a new, more efficient combination drug regimen against TB that is less prone to resistance and allows shortening of treatment duration for TB, and multidrug-resistant TB. Such a drug combination will synergistically target the energy metabolism of Mtb or complementary targets. To achieve this, we will advance recently discovered inhibitors of the Mtb respiratory pathway. In addition, we will target the Mtb specific molecular mechanism that reduces reactive oxygen species in the cell. Finally, we will also target host-factors that are essential for the intracellular survival of Mtb. Together, we present a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce chances of drug resistance
